恩替卡韦联合复方鳖甲软肝片对HBV DNA阳性慢性乙型肝炎肝纤维化患者脾脏弹性指数及门静脉内径的影响

发布时间：2018-04-10 15:20

本文选题：肝纤维化 + 慢性乙型肝炎　；参考：《南京医科大学学报(自然科学版)》2017年11期

【摘要】：目的:观察恩替卡韦联合复方鳖甲软肝片对HBV DNA阳性慢性乙型肝炎患者脾脏弹性指数和门静脉内径的影响。方法:HBV DNA阳性慢性乙型肝炎患者64例,治疗组36例,对照组28例。治疗组恩替卡韦联合复方鳖甲软肝片治疗,对照组恩替卡韦治疗。每3个月查肝功能、甲胎蛋白、HBV DNA、两对半、血常规,上腹部B超检测肝脏和脾脏的弹性指数、门静脉内径,共4次。结果:治疗3个月,两组HBV DNA均已转阴,肝功能、甲胎蛋白、血常规基本正常,肝、脾弹性指数和门静脉内径与基线比无差异;治疗6、9个月,两组血清学检测结果同3个月,但肝、脾弹性指数和门静脉内径与治疗3个月比较,差异有统计学意义,治疗组治疗6、9个月与基线及治疗3个月比较,肝、脾弹性指数和门静脉内径差异有统计学意义;对照组肝、脾弹性指数和门静脉内径与治疗3个月及基线比较无统计学差异;治疗12个月两组肝、脾弹性指数和门静脉内径差异有统计学意义。结论:对HBV DNA阳性慢性乙型肝炎肝纤维化患者进行抗病毒联合抗纤维化治疗后,肝、脾弹性指数和门静脉内径改善的疗效优于单纯抗病毒治疗。
[Abstract]:Aim: to observe the effect of entecavir combined with compound Biejia Ruangan tablets on spleen elasticity index and portal vein diameter in HBV DNA positive patients with chronic hepatitis B.Methods 64 cases of DNA positive chronic hepatitis B patients, 36 cases of treatment group and 28 cases of control group.The treatment group was treated with entecavir combined with compound Biejia Ruangan tablet and the control group was treated with entecavir.Liver function, HBV DNA, two and a half pairs, blood routine were examined every 3 months. The elastic index of liver and spleen and the diameter of portal vein were detected by B ultrasound in upper abdomen for 4 times.Results: after 3 months of treatment, HBV DNA in both groups had turned negative, liver function, alpha-fetoprotein, routine blood routine were basically normal, and there was no difference in the ratio of liver, spleen elasticity index and portal vein diameter to baseline, and the results of serological examination in the two groups were the same as those in 3 months after treatment for 6,9 months.However, there were significant differences in liver, spleen elasticity index and portal vein diameter between the treatment group and the treatment group at 6 months and 9 months, compared with baseline and 3 months, and the difference between liver and spleen elasticity index and portal vein diameter was statistically significant.There was no significant difference in liver, splenic elasticity index and portal vein diameter between the control group and the treatment group at 3 months and baseline, but there were significant differences in the liver, spleen elasticity index and portal vein diameter between the two groups after 12 months of treatment.Conclusion: the improvement of liver and spleen elasticity index and portal vein diameter in HBV DNA positive patients with chronic hepatitis B liver fibrosis is better than that of antiviral therapy alone.
【作者单位】：江苏省中医院感染科;江苏省中医院超声医学科;南京中医药大学第一临床医学院;
【基金】：江苏省中医药局科研项目(YB2015020)
【分类号】：R512.62;R575.2

【相似文献】